Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Posted by ABMN Staff on Mar 18th, 2025

Investment analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Stock Down 0.2 %

NASDAQ:MRNS opened at $0.55 on Tuesday. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $9.69. The stock’s 50-day simple moving average is $0.55 and its 200 day simple moving average is $0.76. The firm has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Marinus Pharmaceuticals during the 4th quarter worth $54,000. World Investment Advisors LLC acquired a new position in Marinus Pharmaceuticals in the 3rd quarter worth about $104,000. Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals in the fourth quarter valued at about $107,000. Finally, XTX Topco Ltd boosted its stake in shares of Marinus Pharmaceuticals by 1,564.7% during the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 206,614 shares in the last quarter. 98.80% of the stock is currently owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.